What is the total number of shares outstanding after the issuance of 230,770 ADSs and the associated warrants, and what percentage dilution does this represent for existing shareholders? | BLTE (Aug 07, 2025) | Candlesense
BLTE

What is the total number of shares outstanding after the issuance of 230,770 ADSs and the associated warrants, and what percentage dilution does this represent for existing shareholders?

Short answer:

The news release does not disclose how many shares (or ADSs) Belite Bio had outstanding before the offering, so the exact post‑offering share count and the precise dilution percentage cannot be calculated from the information provided.

Below is a step‑by‑step explanation of how you would compute the numbers if you know the pre‑offering share count, plus an illustration of the calculation using a hypothetical “baseline” figure.

1. What we need to know

Item Why it matters
Shares (or ADSs) outstanding before the offering (let’s call this S₀) This is the denominator that determines how much ownership each existing shareholder owns before any new shares are added.
Newly issued securities 230,770 ADSs are being sold today (these are immediately added to the share count).
Warrants 230,770 warrants that give the holder the right to purchase another 230,770 ADSs in the future. These are not counted as shares today but will be if the holder exercises them.
Potential additional issuance If all the warrants are exercised, an additional 230,770 ADS will be added later. This is a future dilution, not part of the “immediate” post‑offering share count.

2. How to calculate the post‑offering share count

  1. Immediate post‑offering (after the 230,770 ADS are issued):

[
\text{Total shares after issuance (S₁)} = S₀ + 230{,}770
]

  1. Dilution for existing shareholders (immediate):

[
\text{Dilution\% (immediate)} = \frac{230{,}770}{S₀ + 230{,}770} \times 100\%
]

(This gives the fraction of the total company that the new ADSs represent.)

  1. Potential dilution after warrants are exercised (maximum dilution):

[
\text{Total shares if all warrants are exercised (S₂)} = S₀ + 2 \times 230{,}770
]

[
\text{Dilution\% (maximum)} = \frac{2 \times 230{,}770}{S₀ + 2 \times 230{,}770} \times 100\%
]

3. Example (illustrative only)

Let’s assume—purely for illustration—that Belite Bio had 30 million ADSs outstanding prior to the offering.

Step Calculation Result
Pre‑offering shares (S₀) — 30,000,000
Add the 230,770 newly issued ADSs S₁ = 30,000,000 + 230,770 30,230,770
Immediate dilution 230,770 Ă· 30,230,770 ≈ 0.00764 = 0.76 %
If all warrants are exercised S₂ = 30,000,000 + 2×230,770 = 30,461,540
Maximum dilution (2 × 230,770) Ă· 30,461,540 ≈ 0.0152 = 1.52 %

With a 30‑million‑share base, the new issuance would dilute existing owners by roughly *0.76 %** immediately, and could rise to about 1.5 % if the warrants are all exercised.*

4. What you need to answer the question precisely

  1. Find the current number of ADSs (or shares) outstanding for Belite Bio (BLTE) as of the most recent filing (e.g., the most recent 10‑K, 10‑Q, or 8‑K). This figure is typically disclosed under “Shares outstanding” or “Weighted‑average shares outstanding” in the “Capital Stock” section of the filing, or in the “Shareholder Equity” table of a recent quarterly report.

  2. Plug that figure into the formulas above to calculate:

  • Post‑offering total shares = S₀ + 230,770.
  • Immediate dilution = 230,770 Ă· (S₀ + 230,770).
  • Maximum (potential) dilution = (2 × 230,770) Ă· (S₀ + 2 × 230,770).
  1. Convert the fractions into percentages (multiply by 100) and report them with the appropriate number of decimal places (usually two).

5. How to locate the needed data

Source How to find it
SEC Form 8‑K (the announcement filing) Look for a section titled “Capital Structure,” “Capital Stock,” or “Shareholder Information.” The “Number of Shares Outstanding” is typically listed in the “Item 7.01 – Regulation FD Disclosure” or “Item 8.01 – Other Events” sections.
Form 10‑K/10‑Q (most recent annual or quarterly report) Under “Item 1 – Business” → “Capital Stock” or in the “Consolidated Balance Sheets” where “Common Stock, Shares Issued and Outstanding” is disclosed.
Investor Relations page Companies often provide a “Key Metrics” or “Share Statistics” table that lists the current number of ADSs (or the underlying ordinary shares).
NASDAQ or Bloomberg You can also retrieve the “Shares Outstanding” figure from market data platforms (e.g., Bloomberg terminal, Nasdaq.com).

6. Bottom line

  • Exact answer: Cannot be derived from the press‑release alone because it does not disclose the pre‑offering share count.
  • Methodology: Use the pre‑offering share count (S₀) to add the 230,770 ADSs that were sold. The dilution percentage is simply the proportion of those new ADSs relative to the total after issuance.
  • If you obtain the current share count (for example, 30 million as used in the illustration), the post‑offering total would be S₀ + 230,770 and the immediate dilution would be roughly 0.8 % (with a possible additional 0.8 % if all warrants are exercised).

Next step: Retrieve Belite Bio’s latest share‑count figure from its most recent SEC filing, then apply the formulas above to get the precise numbers you need.

Other Questions About This News

What will be the total potential dilution if the additional $15 million of five‑year warrants are fully exercised, and how does that impact future EPS and cash per share? How will the proceeds (both the $15 million immediate and the potential $15 million from warrant exercises) be allocated – e.g., R&D, clinical trials, debt repayment, or general corporate purposes? What are the pricing and terms of this offering compared with recent financing rounds for Belite Bio and comparable biotech firms? What is the anticipated market reaction to a registered direct offering of this size – could it cause short‑term price pressure or volatility? How might this offering affect the company's current debt covenants or credit facilities? Will there be any covenants, restrictions, or redemption features attached to the ADSs or warrants that could affect shareholder rights or future financing flexibility? What is the exercise price and expiration date of the warrants issued in this offering, and how likely are they to be exercised? How does the $65 per ADS (including the warrant) compare to the current market price of BLTE shares, and what discount or premium does the offering represent? What is the expected impact of this capital raise on the company’s cash runway and its ability to meet upcoming milestones in its retinal disease pipeline? Will existing shareholders have any pre‑emptive rights or the opportunity to participate in the offering? How does this capital raise improve the odds of reaching key clinical milestones and potentially catalyze a stock price rally? What are the potential risks if the company fails to achieve the projected milestones, given the increased capital base? Are there any regulatory or filing deadlines associated with the securities purchase agreement that could impact timing or pricing? What are the specific terms of the warrants (exercise price, settlement method, any lock‑up periods, and anti‑dilution provisions)? What is the anticipated dilution for the five‑year warrants based on historical exercise rates for similar biotech offers?